Skip to content

medcelerator · clinician one-pager

Once-Daily Switch Pill for Adults with Suppressed HIV

Idvynso (doravirine/islatravir) for HIV-1 — switch-only dual tablet

Health Canada/FDA Approved · United States, Canada · September 4, 2026

Condition: HIV

Who this is for

Idvynso (doravirine and islatravir) is a daily pill for adults whose HIV (human immunodeficiency virus) is already under control. Canada and the United States approved it for switching, not for starting treatment.

Next clinical step

Health Canada and the US Food and Drug Administration (FDA) have approved this medicine. In Canada and the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, it is authorised but may not be on sale yet.

Ways to access this treatment

Possible routes (not confirmed)

General resources for further research

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/idvynso-doravirine-islatravir